Mumbai (Maharashtra) [India], February 16: Fabtech Technologies Limited (FTL), a global leader in end-to-end pharmaceutical engineering, has secured a ₹63.6 crore Design-and-Build contract for a comprehensive pharmaceutical manufacturing facility in the West Africa region. The project will support the production of tablets, capsules, liquid syrups, and ointments, significantly enhancing access to affordable medicines across developing markets.
Pioneering Turnkey Pharmaceutical Project in West Africa
The facility is backed by the International Finance Corporation and supported by the United Nations Industrial Development Organization (UNIDO) as part of a broader initiative to strengthen West Africa’s pharmaceutical manufacturing backbone and reduce dependency on imports.
Fabtech will deliver complete end-to-end execution from design and engineering to construction, installation, commissioning, and qualification integrating advanced cleanroom architecture, precision HVAC systems, process automation, and compliant utility engineering, all under a single-source model.
Powered by its proprietary Design–Engineer–Build methodology, Fabtech combines deep technological capability with global regulatory expertise to deliver future-ready, GMP-compliant facilities. With vertically integrated in-house capabilities across air, water, and process systems, Fabtech continues to set the benchmark as the world’s most comprehensive single-source partner for pharmaceutical and biotech infrastructure.
More than a project, this initiative reinforces Fabtech’s mission to make medicines accessible and affordable across emerging economies while supporting sustainable industrial development in West Africa.
Disclaimer
Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
